Literature DB >> 10347331

Effect of long-term beta-blockade on aortic root compliance in patients with Marfan syndrome.

A S Rios1, E N Silber, N Bavishi, P Varga, B K Burton, W A Clark, P Denes.   

Abstract

BACKGROUND: This study was undertaken to assess the effect of long-term beta-blockade on the aortic root stiffness index and distensibility in patients with Marfan syndrome.
METHODS: Aortic root stiffness index and distensibility were calculated according to the formulas of Stefanadis and Hirai, respectively, with 2-dimensional guided M-mode echocardiogram before and after an average of 26 months of atenolol administration.
RESULTS: Twenty-three asymptomatic patients were studied (11 men and 12 women, aged 31 +/- 14.2 years). The follow-up was 4 +/- 2.2 years. The dose of atenolol was individualized (mean 43.5 +/- 21.6 mg/d). Heart rate decreased from 79 +/- 9 beats/min to 64 +/- 9 beats/min (P =. 01), and systolic blood pressure decreased from 124 +/- 13 mm Hg to 114 +/- 2 mm Hg (P =.01). Distensibility increased from 1.85 +/- 0. 70 x 10(-6) cm2/dynes-1 to 2.21 +/- 0.76 x 10-6 cm2/dynes-1 (P =.02), and the stiffness index decreased from 9.68 +/- 3.78 to 8.85 +/- 3. 15 ( P =.2). Two groups of responses to treatment were identified. Compared with baseline values 15 (65%) patients who responded to treatment had increased distensibility and decreased stiffness index of the aortic root (P =.05). Eight patients (35%) who did not respond to treatment had no significant change. Body weight >91 kg and baseline end-diastolic aortic root diameter >40 mm were significantly associated with no response (P =.05). Two patients in the nonresponding group had echocardiographic progression of aortic insufficiency.
CONCLUSIONS: There was a heterogeneous response in the aortic root elastic properties after long-term treatment with atenolol in asymptomatic patients with Marfan syndrome. Stiffness index and distensibility are more likely to respond when the baseline end-diastolic aortic root diameter is <40 mm.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10347331     DOI: 10.1016/s0002-8703(99)70362-5

Source DB:  PubMed          Journal:  Am Heart J        ISSN: 0002-8703            Impact factor:   4.749


  13 in total

Review 1.  Management of Marfan syndrome.

Authors:  John C S Dean
Journal:  Heart       Date:  2002-07       Impact factor: 5.994

2.  Report of the National Heart, Lung, and Blood Institute and National Marfan Foundation Working Group on research in Marfan syndrome and related disorders.

Authors:  Gail D Pearson; Richard Devereux; Bart Loeys; Cheryl Maslen; Dianna Milewicz; Reed Pyeritz; Francesco Ramirez; Daniel Rifkin; Lynn Sakai; Lars Svensson; Andy Wessels; Jennifer Van Eyk; Harry C Dietz
Journal:  Circulation       Date:  2008-08-12       Impact factor: 29.690

Review 3.  Marfan syndrome. Part 2: treatment and management of patients.

Authors:  Victoria Cañadas; Isidre Vilacosta; Isidoro Bruna; Valentin Fuster
Journal:  Nat Rev Cardiol       Date:  2010-03-30       Impact factor: 32.419

4.  Pregnancy and Marfan syndrome.

Authors:  Sorel Goland; Uri Elkayam
Journal:  Ann Cardiothorac Surg       Date:  2017-11

5.  Medical management of aortic disease in Marfan syndrome.

Authors:  Syed Usman Bin Mahmood; Camilo A Velasquez; Mohammad A Zafar; Ayman A Saeyeldin; Adam J Brownstein; Bulat A Ziganshin; John A Elefteriades; Sandip K Mukherjee
Journal:  Ann Cardiothorac Surg       Date:  2017-11

Review 6.  Cardiovascular Management of Adults with Marfan Syndrome.

Authors:  Yukiko Isekame; Sabiha Gati; Jose Antonio Aragon-Martin; Rachel Bastiaenen; Sreenivasa Rao Kondapally Seshasai; Anne Child
Journal:  Eur Cardiol       Date:  2016-12

Review 7.  Large ascending aortic aneurysm and severe aortic regurgitation in a 7-year-old child with Marfan syndrome and a review of the literature. Marfan syndrome in childhood.

Authors:  Mehmet Yazici; Serdar Soydinç; Vedat Davutoğlu; Ilyas Akdemir; M Hakan Dinçkal
Journal:  Int J Cardiovasc Imaging       Date:  2004-08       Impact factor: 2.357

8.  Long-term effects of losartan on structure and function of the thoracic aorta in a mouse model of Marfan syndrome.

Authors:  H H Clarice Yang; Jong Moo Kim; Elliott Chum; Cornelis van Breemen; Ada W Y Chung
Journal:  Br J Pharmacol       Date:  2009-10-08       Impact factor: 8.739

9.  Aortic pressure-area relation in Marfan patients with and without beta blocking agents: a new non-invasive approach.

Authors:  G J Nollen; B E Westerhof; M Groenink; A Osnabrugge; E E van der Wall; B J M Mulder
Journal:  Heart       Date:  2004-03       Impact factor: 5.994

10.  Influence of Aortic Stiffness on Aortic-Root Growth Rate and Outcome in Patients With the Marfan Syndrome.

Authors:  Elif Seda Selamet Tierney; Jami C Levine; Lynn A Sleeper; Mary J Roman; Timothy J Bradley; Steven D Colan; Shan Chen; M Jay Campbell; Meryl S Cohen; Julie De Backer; Haleh Heydarian; Arvind Hoskoppal; Wyman W Lai; Aimee Liou; Edward Marcus; Arni Nutting; Aaron K Olson; David A Parra; Gail D Pearson; Mary Ella Pierpont; Beth F Printz; Reed E Pyeritz; William Ravekes; Angela M Sharkey; Shubhika Srivastava; Luciana Young; Ronald V Lacro
Journal:  Am J Cardiol       Date:  2018-02-13       Impact factor: 2.778

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.